Publication for PTPRC and PTPN22

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	PTPRC	protein tyrosine phosphatase receptor type C	5788			[link]
hsa	PTPN22	protein tyrosine phosphatase non-receptor type 22	26191

Pubmed ID	Priority	Text
22816879	0.98	Lyp, HePTP and FAP1, the receptor-like PTPs, CD45, LAR, and PTPalpha, the dual specificity phosphatases VHR, and Cdc14, and the low molecular weight PTP.
	0.98	CD45, LAR, VHX and the low molecular weight PTP, and no inhibition at 100 muM against LYP, PTPalpha, VHR and Cdc14.
	0.98	Lyp with an IC50 value of 0.508 muM. Michaelis-Menten kinetic analysis revealed inhibition patterns ranging from competitive to mixed for compound 18 with a calculated Ki of 0.384 muM. The selectivity of compound 18 for Lyp ranged from 3-fold over TC-PTP and PTP1B, 46-fold over SHP1, 59-fold over CD45, and up to >200-fold over PTP-PEST.
	0.97	Lyp, HePTP, CD45, PTPbeta, PTPgamma, PTPRO, VHR, MKP-1, MKP-3, Cdc25, YopH, mPTPA, and mPTPB.
	0.97	Lyp, 41.2 muM for PTP1B, and greater than 50 muM for HePTP, PTPalpha, CD45, VHR and Cdc14.
	0.97	Lyp, exhibiting, with one exception (PTP1B, 2.6-fold), >7-fold selectivity against all PTPs (SHP2, HePTP, PTP-MEG2, FAP-1, VHR, CD45, LAR, and PTPalpha) examined.
	0.97	Lyp with an IC50 of 1.5 muM and had a 10-fold selectivity for Lyp over PTP-PEST, HePTP, and CD45.
	0.97	Lyp, TC-PTP, SHP1, SHP2, CD45 and LAR.
	0.97	Lyp and FAP1, the receptor-like PTPs, CD45, LAR, and PTPalpha, the dual specificity phosphatases VHR, VHX, Cdc14, and the low molecular weight PTP.
	0.96	Lyp, HePTP, CD45, PTPbeta, PTPgamma, PTPRO, VHR, MKP-1, MKP-3, Cdc25, YopH, mPTPA, and mPTPB.
	0.95	Lyp, HePTP, PTP-Meg2, and FAP1, the receptor-like PTPs, CD45, LAR, and PTPalpha, the dual specificity phosphatase VHR, VHX, and CDC14A, and the low molecular weight PTP.
23873737	0.98	LYP activity (IC50 = 47 +- 2 muM), but surprisingly did not inhibit the activity of PTP-PEST or CD45 at concentrations up to 500 muM. The product of disulfiram reduction and known metabolite of the drug, diethyldithiocarbamate, had no activity against LYP, PTP-PEST or CD45.
	0.97	LYP preferentially over CD45 both in vitro and in Jurkat T-cells.
	0.96	LYP-selective inhibitor with cellular activity would be expected to induce an increase in phosphorylation at Y394 only, while a CD45 inhibitor would induce an increase in phosphorylation at both Y394 and Y505.
	0.96	LYP and CD45 inhibition study are shown in Figure 2.
	0.96	LYP over CD45 in cells.
	0.89	LYP and CD45 activity by disulfiram and diethyldithiocarbamate.
23300686	0.98	protein tyrosine phosphatase CD45 in pancreatic cells, we suggest that peroxytetradecanoic acid being a potential lipase-catalyzed product might be an unexpected regulator of CD45 activity.
	0.97	protein tyrosine phosphatase CD45 in pancreatic cells, we suggest that peroxy acids may be unexpected potential regulators of CD45 activity.
	0.97	protein tyrosine phosphatase CD45, being effective in nanomolar concentrations.
	0.97	protein tyrosine phosphatase CD45 expressed in the acinar cells due to peroxy acids formation may be implicated in the development and exacerbation of acute pancreatitis.
	0.78	Protein tyrosine phosphatase CD45 is one of the key regulatory enzymes abundantly expressed in leukocytes.
25108421	0.98	CD45.1+ and Ptpn22-/- CD45.2+ OT-1 cells were mixed ~1:1 and transferred i.v. to Rag1-/- hosts.
	0.95	CD45.1+ and Ptpn22-/- (KO) CD45.2+ Rag1-/- OT-1 cells at a ~1:1 ratio to Rag1-/- hosts followed by LmOva infection (n=6 mice/group).
	0.63	CD45-congenic WT and Ptpn22-/- OT-1 T cells were mixed 1:1 and transferred to Rag1-/- recipients which were either infected with LmOva or left uninfected.
20682913	0.98	protein tyrosine phosphatase (PTP) CD45 is proposed to inhibit proximal TCR signals.
	0.76	PTP CD45 was proposed to directly dephosphorylate pTyr505, whereas SHP-2-mediated dephosphorylation of the adaptor protein PAG may inhibit the recruitment of Csk to PAG and the subsequent inhibitory phosphorylation of Lck at Tyr505.
21341673	0.98	CD45 and LYP, through its two major phosphorylation sites at Y505 (a negative regulator of Lck activation) and Y394 (a positive regulator of Lck activation), respectively.
21190368	0.97	Lyp but is rather dephosphorylated by CD45, leading to a conformational change and increased catalytic activity of Lck.
	0.97	Lyp over HePTP and LAR by about 1-2 orders of magnitude, and over CD45 by up to 3.3-fold.
	0.97	Lyp's direct substrates Lck-pY394 and the phosphorylated ITAMs of the zeta-chains associated with the TCR, as well as on Lck's negative regulatory site pY505, which is controlled by the CD45 phosphatase.
	0.94	Lyp over CD45 and, especially, over HePTP and LAR.
22426112	0.97	LYP, SHP1, PTPH1, PTP-MEG1, and perhaps CD45 and PTP-PEST.
	0.97	LYP inhibitor reported to date, and, more importantly, was found to be selective for inhibiting LYP over the closely related phosphatases PTP-PEST, SHP1, CD45, TCPTP, and PTP1B.
	0.83	LYP ranged from 3-fold over TCPTP (IC50 = 1.52 muM) and PTP1B (IC50 = 1.59 muM), 46-fold over SHP1 (IC50 = 23.2 muM), and 59-fold over CD45 (IC50 = 30.1muM), up to greater than 200-fold over PTP-PEST (IC50 > 100 muM).
30720103	0.97	CD45 is a protein tyrosine phosphatase (PTP), that is expressed by hematopoietic cells, with the exception of platelets and mature erythrocytes.
	0.79	PTP is encoded by the PTPRC gene located on chromosome 1.
22682003	0.97	CD45 is the prototypical receptor protein tyrosine phosphatase and the first to have been identified as such.
29116089	0.97	Ptpn22 -/- CD45.2+ OT-1 cells (1 x 106 of each).
25013476	0.96	PTPase inhibitor, phenylarsine oxide, and a CD45 inhibitor reversed the IL-10-induced impaired differentiation of the DCs, and also reversed the induction of the TADCs by A549, MDA-MB-231 and SW480 conditioned media, which thus represents a novel therapy to reduce immune surveillance in the tumor microenvironment.
	0.96	CD45 PTPase activity is required for IL-10-mediated TADC differentiation, and that PAO and CD45 inhibitors block this process, which indicates that there is potential for the use of small molecules to modulate the immune system in the tumor microenvironment.
	0.95	PTPase inhibitor, PAO, and CD45i reversed the IL-10-induced TADCs, however, PTP inhibitor XVIII was not found to block CD45 activity or the IL-10-mediated differentiation of the TADCs.
	0.83	CD45 PTPase inhibitor (CD45 i.) or 50 nM PTP inhibitor XVIII (PTPi.
	0.74	CD45 PTPase was determined using a CD45 Tyrosine Phosphatase assay kit.
19888762	0.96	LYP over PTP-PEST with peptide 1 as the substrate, but also showed significant inhibition of CD45.
	0.92	LYP as well as its activation by dephosphorylation at Y505 by CD45.
	0.80	LYP with both substrates and were also selective for LYP over HePTP and CD45, two other PTPs involved in T-cell receptor signaling.
	0.75	LYP over PTP-PEST, HePTP and CD45 in vitro.
11423001	0.96	CD45 gene indicates that both protein tyrosine phosphatase (PTPase) domains have a very similar exon/intron organization, which probably arose by duplication.
19467874	0.96	protein tyrosine phosphatase alpha (RPTPalpha), leucocyte antigen-related phosphatase (LAR) and CD45, results in their inactivation.
28534914	0.96	LYP, and over 14 fold selectivity against PTP-PEST, HePTP, and CD45.
28393080	0.94	PTPN22 and PTPRC have been associated with human autoimmune diseases, including multiple sclerosis and autoimmune hepatitis in the case of PTPRC and type I diabetes, rheumatoid arthritis, and systemic lupus erythematosus in the case of PTPN22.
	0.92	PTPRC (CD45), PTPN1 (PTP1B), PTPN7 (HePTP), PTPN6 (SHP1), PTPRJ (CD148 or DEP-1), PTPN4 (MEG1), PTPN12 (PTP-PEST), PTPN2 (TC-PTP), PTPN22 (LYP), and PTPRA (PTP-alpha) (Figure 2).
19147543	0.94	CD45 and PTP-epsilon.
23886911	0.94	CD45, HePTP, PTP1B, PTP-PEST and 1 ug LYP samples were either treated with 50 mM iodoacetic acid (IAA) or left untreated (0 mM), boiled for 4 min at 95 C and run on the phosphogram gel.
19167335	0.92	LYP; Category II: IA2, IA2beta; Category III: LAR, RPTPsigma; Category IV: PTPH1, MEG1, PTPD2, CD45; Category V: STEP, HEPTP, PCPTP1.
	0.63	CD45 and LAR reveal that PTP catalytic domains do not dimerize in solution under physiological buffer conditions and provide strong evidence against the long-held inhibitory wedge model.
23713581	0.87	LYP, their inhibitory activity toward a panel of mammalian PTPs including cytosolic PTPs, PTP1B, SHP1, SHP2, TC-PTP, HePTP, PTP-Meg2, PTP-PEST, FAP1, and PTPH1, the receptor-like PTPs, CD45, LAR, PTPalpha, PTPbeta, PTPepsilon, PTPgamma, PTPmicro, and PTPsigma, the dual specificity phosphatases Laforin, VHR, VHX, VHZ, MKP3, and Cdc14, and the low molecular weight PTP were measured.
32047502	0.82	CD45.1 PTPN22 WT, CD45.1/2 PTPN22 R619W and CD45.2 PTPN22 KO CD8 OT-1 cells in a 1:1:1 ratio into lymphopenic Rag-1 KO hosts.
20204370	0.80	PTPN22, PTPN2, PTPRC, UBASH3A, PTPN11, and PTPRT).
	0.72	CD45 wedge model is driven by increased TCR and BCR signaling, the results of Zikherman et al. suggest that inhibition of LYP might be counterproductive in diseases or subsets of diseases with a strong component of TCR or BCR hyperactivity (which has been observed in large subsets of lupus patients) and thus not easily extended to noncarriers of gain-of-function LYP mutation(s).
19290935	0.73	CD45 antibodies and Lyp inhibitors that are currently being developed.
24997687	0.62	LYP (circles) CD45 (squares), PTP1B (diamonds) and YopH (triangles) by compound 1h, 1,2-dihydroxynaphthalene.
31096440	0.62	PTPN22 belongs to class I protein tyrosine phosphatases (PTPs), and its catalytic domain is highly homologous to the catalytic domains of other classical tyrosine-specific PTPs with known immune system functions, including CD45, SHP-1, and TC-PTP.